CAR-T cell therapy has been proven effective in pediatric and adult acute lymphocytic leukemia, B cell lymphoma, mantle cell lymphoma, and multiple myeloma by targeting the Cluster of Differentiation 19 (CD19) or B cell maturation antigen (BCMA) on these malignant cells (Asmamaw et al., 2022). Here, TNFRSF17 is linked to B-cell non-Hodgkin lymphoma.